Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

被引：4

作者：

Salwender, Hans ^{[1
]}

Elmaagacli, Ahmet ^{[2
]}

Merz, Maximilian ^{[3
]}

Miah, Kaya ^{[4
]}

Benner, Axel ^{[4
]}

Haenel, Mathias ^{[5
]}

Jehn, Christian ^{[2
]}

Mai, Elias K. ^{[6
]}

Bertsch, Uta ^{[6
,7
]}

Blau, Igor W. ^{[8
]}

Scheid, Christof ^{[9
]}

Hose, Dirk ^{[10
]}

Seckinger, Anja ^{[10
]}

Jauch, Anna ^{[11
]}

Raab, Marc S. ^{[6
]}

Luntz, Steffen P. ^{[12
]}

Besemer, Britta ^{[13
]}

Munder, Markus ^{[14
]}

Brossart, Peter ^{[15
]}

Fuhrmann, Stephan ^{[16
]}

Lindemann, Hans-Walter ^{[17
]}

Weisel, Katja ^{[18
]}

Duerig, Jan ^{[19
]}

Goldschmidt, Hartmut ^{[6
,7
]}

机构：

[1] AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[2] Allgemein Krankenhaus St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[3] Univ Hosp Leipzig, Dept Hematol Celltherapy & Hemostaseol, Leipzig, Germany

[4] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[5] Klinikum Chemnitz, Chemnitz, Germany

[6] Univ Heidelberg Hosp, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[8] Charite, Berlin, Germany

[9] Univ Hosp Cologne, Cologne, Germany

[10] Vrije Univ Brussel VUB, Lab Hematol & Immunol & Labor Myelomforsch, Jette, Belgium

[11] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[12] Coordinat Ctr Clin Trials KKS, Heidelberg, Germany

[13] Univ Tubingen Hosp, Tubingen, Germany

[14] Univ Med Ctr Mainz, Mainz, Germany

[15] Univ Hosp Bonn, Bonn, Germany

[16] Helios Hosp Berlin Buch, Buch, Germany

[17] Kath Krankenhaus Hagen, Hagen, Germany

[18] Univ Hamburg Hosp, Hamburg, Germany

[19] Univ Hosp Essen, Essen, Germany

来源：

LEUKEMIA | 2021年 / 35卷 / 10期

关键词：

PERIPHERAL NEUROPATHY; DEXAMETHASONE; LENALIDOMIDE;

D O I：

10.1038/s41375-021-01298-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3007 / 3011

页数：5

共 50 条

[1] Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender
Ahmet Elmaagacli
Maximilian Merz
Kaya Miah
Axel Benner
Mathias Haenel
Christian Jehn
Elias K. Mai
Uta Bertsch
Igor W. Blau
Christof Scheid
Dirk Hose
Anja Seckinger
Anna Jauch
Marc S. Raab
Steffen P. Luntz
Britta Besemer
Markus Munder
Peter Brossart
Stephan Fuhrmann
Hans-Walter Lindemann
Katja Weisel
Jan Duerig
Hartmut Goldschmidt
Leukemia, 2021, 35 : 3007 - 3011
[2] Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma - Subgroup Analysis from the GMMG-MM5 Trial
Merz, Maximilian
Salwender, Hans
Haenel, Mathias
Bertsch, Uta
Kunz, Christina
Hielscher, Thomas
Blau, Igor W.
Scheid, Christof
Mai, Elias Karl
Hose, Dirk
Schurich, Baerbel
Munder, Markus
Schmidt-Wolf, Ingo G. H.
Gerecke, Christian
Lindemann, Hans Walter
Zeis, Matthias
Weisel, Katja
Duerig, Jan
Goldschmidt, Hartmut
BLOOD, 2014, 124 (21)
[3] Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Merz, Maximilian
Salwender, Hans
Haenel, Mathias
Mai, Elias K.
Bertsch, Uta
Kunz, Christina
Hielscher, Thomas
Blau, Igor W.
Scheid, Christof
Hose, Dirk
Seckinger, Anja
Jauch, Anna
Hillengass, Jens
Raab, Marc S.
Schurich, Baerbel
Munder, Markus
Schmidt-Wolf, Ingo G. H.
Gerecke, Christian
Lindemann, Hans-Walter
Zeis, Matthias
Weisel, Katja
Duerig, Jan
Goldschmidt, Hartmut
HAEMATOLOGICA, 2015, 100 (07) : 964 - 969
[4] Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
Merz, Maximilian
Salwender, Hans
Haenel, Mathias
Mai, Elias K.
Bertsch, Uta
Kunz, Christina
Hielscher, Thomas
Blau, Igor W.
Scheid, Christof
Hose, Dirk
Seckinger, Anja
Jauch, Anna
Hillengass, Jens
Raab, Marc S.
Schurich, Baerbel
Munder, Markus
Brossart, Peter
Gerecke, Christian
Lindemann, Hans-Walter
Zeis, Matthias
Weisel, Katja
Duerig, Jan
Goldschmidt, Hartmut
HAEMATOLOGICA, 2016, 101 (12) : E485 - E487
[5] Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Salwender, Hans
Weinhold, Niels
Benner, Axel
Miah, Kaya
Merz, Maximilian
Haenel, Mathias
Jehn, Christian
Mai, Elias
Menis, Ekaterina
Blau, Igor
Scheid, Christof
Hose, Dirk
Seckinger, Anja
Luntz, Steffen
Besemer, Britta
Munder, Markus
Brossart, Peter
Glass, Bertram
Lindemann, Hans-Walter
Weisel, Katja
Hanoun, Christine
Schnitzler, Paul
Klemm, Sarah
Goldschmidt, Hartmut
Raab, Marc
Elmaagacli, Ahmet
HEMATOLOGY, 2024, 29 (01)
[6] Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Salwender, Hans-Juergen
Van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Blau, Igor W.
Zweegman, Sonja
Weisel, Katja C.
Vellenga, Edo
Pfreundschuh, Michael
Broijl, Annemiek
Scheid, Christof
Wittebol, Shulamiet
Bos, Gerard M. J.
Stevens-Kroef, Marjan
Jauch, Anna
Potamianou, Anna
Hose, Dirk
Raymakers, Reinier
Schaafsme, Marinus
Kersten, Marie Jose
Kooy, Marinus van Marwijk
Duehrsen, Ulrich
Lindemann, Hans Walter
Brossart, Peter
Wijermans, Pierre
Lokhorst, Henk M.
Goldschmidt, Hartmut
BLOOD, 2015, 126 (23)
[7] Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt
Elias K. Mai
Jan Dürig
Christof Scheid
Katja C. Weisel
Christina Kunz
Uta Bertsch
Thomas Hielscher
Maximilian Merz
Markus Munder
Hans-Walter Lindemann
Barbara Hügle-Dörr
Diana Tichy
Nicola Giesen
Dirk Hose
Anja Seckinger
Stefanie Huhn
Steffen Luntz
Anna Jauch
Ahmet Elmaagacli
Bernhard Rabold
Stephan Fuhrmann
Peter Brossart
Martin Goerner
Helga Bernhard
Martin Hoffmann
Jens Hillengass
Marc S. Raab
Igor W. Blau
Mathias Hänel
Hans J. Salwender
Leukemia, 2020, 34 : 1853 - 1865
[8] Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Goldschmidt, Hartmut
Mai, Elias K.
Duerig, Jan
Scheid, Christof
Weisel, Katja C.
Kunz, Christina
Bertsch, Uta
Hielscher, Thomas
Merz, Maximilian
Munder, Markus
Lindemann, Hans-Walter
Huegle-Doerr, Barbara
Tichy, Diana
Giesen, Nicola
Hose, Dirk
Seckinger, Anja
Huhn, Stefanie
Luntz, Steffen
Jauch, Anna
Elmaagacli, Ahmet
Rabold, Bernhard
Fuhrmann, Stephan
Brossart, Peter
Goerner, Martin
Bernhard, Helga
Hoffmann, Martin
Hillengass, Jens
Raab, Marc S.
Blau, Igor W.
Haenel, Mathias
Salwender, Hans J.
LEUKEMIA, 2020, 34 (07) : 1853 - 1865
[9] Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
Huhn, S.
Weinhold, N.
Nickel, J.
Pritsch, M.
Hielscher, T.
Hummel, M.
Bertsch, U.
Huegle-Doerr, B.
Vogel, M.
Angermund, R.
Haenel, M.
Salwender, H. J.
Weisel, K.
Duerig, J.
Goerner, M.
Kirchner, H.
Peter, N.
Graeven, U.
Lordick, F.
Hoffmann, M.
Reimer, P.
Blau, I. W.
Jauch, A.
Dembowsky, K.
Moehler, T.
Wuchter, P.
Goldschmidt, H.
BONE MARROW TRANSPLANTATION, 2017, 52 (08) : 1194 - 1198
[10] Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
S Huhn
N Weinhold
J Nickel
M Pritsch
T Hielscher
M Hummel
U Bertsch
B Huegle-Doerr
M Vogel
R Angermund
M Hänel
H J Salwender
K Weisel
J Dürig
M Görner
H Kirchner
N Peter
U Graeven
F Lordick
M Hoffmann
P Reimer
I W Blau
A Jauch
K Dembowsky
T Möhler
P Wuchter
H Goldschmidt
Bone Marrow Transplantation, 2017, 52 : 1194 - 1198

← 1 2 3 4 5 →